

32692

Customer Number

Patent
Case No.: 58751US010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: MILLER, RICHARD L.
Application No.: 10/595117 Confirmation No.: 2906
Filed: September 1, 2004
Title: METHODS RELATED TO THE TREATMENT OF MUCOSAL ASSOCIATED
CONDITIONS

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

If a first Office Action on the merits has been mailed prior to the mailing date of this document, please charge the fee for consideration of an Information Disclosure Statement set forth in 37 CFR § 1.17(p).

Respectfully submitted,

Aug. 21, 2006
Date

By: Ted K. Ringsred
Ted K. Ringsred, Reg. No.: 35,658
Telephone No.: 651-736-5839

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-3833

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 1 of 4	Application Number	10/595117
	Filing Date	September 1, 2004
	First Named Inventor	Miller, Richard L.
	Confirmation Number	2906
	Attorney Case Number	58751US010

U.S. Patent Documents					
Exam. Init.*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 4,689,338	08-25-1987	Gerster	
	A2	US- 4,929,624	05-29-1990	Gerster et al.	
	A3	US- 4,988,815	01-29-1991	André et al.	
	A4	US- 5,037,986	08-06-1991	Gerster	
	A5	US- 5,175,296	12-29-1992	Gerster	
	A6	US- 5,238,944	08-24-1993	Wick et al.	
	A7	US- 5,266,575	11-30-1993	Gerster et al.	
	A8	US- 5,268,376	12-07-1993	Gester	
	A9	US- 5,346,905	09-13-1994	Gerster	
	A10	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A11	US- 5,367,076	11-22-1994	Gerster	
	A12	US- 5,389,640	02-14-1995	Gerster et al.	
	A13	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A14	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A15	US- 5,482,936	01-09-1996	Lindstrom	
	A16	US- 5,693,811	12-02-1997	Lindstrom	
	A17	US- 5,741,908	04-21-1998	Gerster et al.	
	A18	US- 5,756,747	05-26-1998	Gerster	
	A19	US- 5,939,090	08-17-1999	Beaurline et al.	
	A20	US- 6,028,076	02-22-2000	Hirota et al.	
	A21	US- 6,039,969	03-21-2000	Tomai et al.	
	A22	US- 6,069,149	05-30-2000	Nanba et al.	
	A23	US- 6,083,505	07-04-2000	Miller et al.	
	A24	US- 6,110,929	08-29-2000	Gerster et al.	
	A25	US- 6,194,388	02-27-2001	Krieg et al.	
	A26	US- 6,194,425	02-27-2001	Gerster et al.	
	A27	US- 6,207,646	03-27-2001	Krieg et al.	
	A28	US- 6,239,116	05-29-2001	Krieg et al.	

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 2 of 4	Application Number	10/595117
	Filing Date	September 1, 2004
	First Named Inventor	Miller, Richard L.
	Confirmation Number	2906
	Attorney Case Number	58751US010

U.S. Patent Documents					
Exam. Init.*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A29	US- 6,245,776	06-12-2001	Skwierczynski et al.	
	A30	US- 6,329,381	12-11-2001	Kurimoto et al.	
	A31	US- 6,331,539	12-18-2001	Crooks et al.	
	A32	US- 6,339,068	01-15-2002	Krieg et al.	
	A33	US- 6,376,501	04-23-2002	Isobe et al.	
	A34	US- 6,376,669	04-23-2002	Rice et al.	
	A35	US- 6,387,938	05-14-2002	Mizuguchi et al.	
	A36	US- 6,406,705	06-18-2002	Davis et al.	
	A37	US- 6,426,334	07-30-2002	Agrawal et al.	
	A38	US- 6,451,810	09-17-2002	Coleman et al.	
	A39	US- 6,476,000	11-05-2002	Agrawal	
	A40	US- 6,518,265	02-11-2003	Kato et al.	
	A41	US- 6,525,064	02-25-2003	Dellaria et al.	
	A42	US- 6,541,485	04-01-2003	Crooks et al.	
	A43	US- 6,545,016	04-08-2003	Dellaria et al.	
	A44	US- 6,545,017	04-08-2003	Dellaria et al.	
	A45	US- 6,558,951	05-06-2003	Tomai et al.	
	A46	US- 6,573,273	06-03-2003	Crooks et al.	
	A47	US- 6,656,938	12-02-2003	Crooks et al.	
	A48	US- 6,660,735	12-09-2003	Crooks et al.	
	A49	US- 6,660,747	12-09-2003	Crooks et al.	
	A50	US- 6,664,260	12-16-2003	Charles et al.	
	A51	US- 6,664,264	12-16-2003	Dellaria et al.	
	A52	US- 6,664,265	12-16-2003	Crooks et al.	
	A53	US- 6,667,312	12-23-2003	Bonk et al.	
	A54	US- 6,670,372	12-30-2003	Charles et al.	
	A55	US- 6,677,347	01-13-2004	Crooks et al.	
	A56	US- 6,677,348	01-13-2004	Heppner et al.	

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 3 of 4	Application Number	10/595117
	Filing Date	September 1, 2004
	First Named Inventor	Miller, Richard L.
	Confirmation Number	2906
	Attorney Case Number	58751US010

U.S. Patent Documents					
Exam. Init.*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A57	US- 6,677,349	01-13-2004	Griesgraber	
	A58	US- 6,683,088	01-27-2004	Crooks et al.	
	A59	US- 6,756,382	06-29-2004	Coleman et al.	
	A60	US- 6,854,444	02-15-2005	Plagge et al.	
	A61	US- 2002/0016332	02-07-2002	Slade	
	A62	US- 2002/0055517	05-09-2002	Smith	
	A63	US- 2002/0110840	08-15-2002	Tomai et al.	
	A64	US- 2003/0133913	07-17-2003	Tomai et al.	
	A65	US- 2003/0199538	10-23-2003	Skwierczynski et al.	
	A66	US- 2004/0014779	01-22-2004	Gorden et al.	

Foreign Patent Documents							
Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1	PCT	WO 02/22125	03-21-2002			
	B2	PCT	WO 02/24225	03-28-2002			
	B3	PCT	WO 03/045391	06-05-2003			
	B4	PCT	WO 04/058759	07-15-2004			
	B5	PCT	WO 05/020995	03-10-2005			
	B6	CA	2 346 634	06-08-2000			
	B7	JP	9-255926	03-26-1999			
	B8	EP	0 394 026	09-29-1993			
	B9	EP	1 256 582	11-13-2002			

OTHER DOCUMENTS			
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Davis et al., "Self-Administered Topical Imiquimod Treatment of Vulvar Intraepithelial Neoplasia", Journal of Reproductive Medicine, Volume 45, Number 8, p 619-623, Aug. 23	
	C2	Diaz-Arrastia et al., "Clinical and Molecular Responses in High-Grade Intraepithelial Neoplasia Treated with Topical Imiquimod 5%", Clinical Cancer Research, Volume 7, p 3031-3033, October 2001	

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO (modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Page 4 of 4	Application Number	10/595117
	Filing Date	September 1, 2004
	First Named Inventor	Miller, Richard L.
	Confirmation Number	2906
	Attorney Case Number	58751US010

OTHER DOCUMENTS			
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C3	Fujisawa et al., "Effect of a Novel Topical Immunomodulator, S-28463, on Kertinocyte Cytokine Gene Expression and Production," abstract, Journal of Interferon and Cytokine Research, 16/7, p. 555-559, (1996).	
	C4	Geisse et al., "Imiquimod 5% cream for the treatment of superticial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study", J. Am. Acad. Dermatol., 47(3): 390-398	
	C5	Henнге et al., "Topical immunomodulators—progress towards treating inflammation, infection, and cancer.", abstract, Lancet Infectious Disease, 1(3), p.189-198, (2001).	
	C6	Jayne et al., "Treatment of Vulvar Intraepithelial Neoplasia 2/3 with Imiquimod", The Journal of Reproductive Medicine, Volume 47, Number 5, p 395-398, May 2002	
	C7	Kaspari et al., "Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma", British Journal of Dermatology, 147, p 757-759, (2002)	
	C8	Pehoushek et al., "Imiquimod and 5% Fluorouracil Therapy for Anal and Perianal Squamous Cell Carcinoma In Situ in an HIV-1-Positive Man", Arch Dermatol. Volume 137, p 14-16, January 2001	
	C9	Salat et al., "Imiquimod 5% anal tampons for intraanal condylomata acuminata", International Journal of STD & AIDS, Volume 13, Supplement 1, p 54, (2002)	
	C10	Shumack et al., "Efficacy of Topical 5% Imiquimod Cream for the Treatment of Nodular Basal Cell Carcinoma", Arch. Dermatol., 138: 1165-1178 (2002)	
	C11	Todd et al., "The effects of 5% imiquimod Cream on High-Grade Vulval Intraepithelial Neoplasia", Gynecologic Oncology, 85, p 67-70, (2002)	
	C12	Travis et al., "Successful Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod 5% Cream in a Lung Transplanted Patient", Letters to the Editor, Acta Derm Venereol 82, p 475-476	
	C13	Van Seters et al., "Imiquimod in the Treatment of Multifocal Vulvar Intraepithelial Neoplasia 2/3, Results of a Pilot Study", The Journal of Reproductive Medicine, Volume 47, Number 9, p. 701-705, September 2002	

*Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	